Region Stockholm and Karolinska Institutet have unveiled recruiting efforts for a clinical trial examining the impact of dapagliflozin on atrial fibrillation recurrence after cardioversion. This study is set to provide critical insights for healthcare providers, regulatory specialists, and device innovators interested in cardiovascular drug interventions.
In this article:
What changed?
The trial, registered as NCT07187570, focuses on dapagliflozin, taken at a fixed dosage of 10 mg once daily, to explore its effects on minimizing atrial fibrillation recurrence post-cardioversion. Region Stockholm and Karolinska Institutet are leading this recruitment effort, targeting patients with a diagnosis of atrial fibrillation (AF).
Trial overview
Study sponsors
The trial is jointly sponsored by Region Stockholm and Karolinska Institutet, institutions renowned for advancing medical research and integrating clinical practices.
Intervention details
Participants will be randomized into two groups: one receiving dapagliflozin and the other following usual care protocols. Dapagliflozin, already in use for other cardiovascular and diabetes-related indications, is administered at a dose of 10 mg daily.
Recruitment status
Recruitment is currently open, as per the latest information on October 5, 2025. Eligible patients with AF will undergo cardioversion before being enrolled in the study.
Why this matters
Atrial fibrillation is a significant global health concern. It raises risks for stroke, heart failure, and other complications. Dapagliflozin, primarily marketed for managing diabetes and heart failure, has shown promise in broader applications for cardiovascular health.
By evaluating its performance against usual care, the trial aims to inform treatment protocols and regulatory strategies for addressing AF recurrence. Insights from this study may also guide device developers working on cardiovascular monitoring systems.
This study aligns closely with regulatory trends emphasizing evidence-based approaches and real-world applications in cardiovascular disease management.
FAQ
- What is dapagliflozin? Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor used for diabetes management and reducing the risk of heart failure events.
- Who can participate in this trial? Patients diagnosed with AF and scheduled for cardioversion are eligible for recruitment.
- What is the trial’s primary goal? To assess whether dapagliflozin reduces the recurrence of atrial fibrillation compared to usual care after cardioversion.
Conclusion
This clinical trial illuminates the evolving role of dapagliflozin in cardiovascular treatment. For regulatory professionals, clinicians, and device developers, the results may offer actionable insights into managing atrial fibrillation more effectively.
Disclaimer
This content is intended for informational purposes only. It should not be construed as legal or clinical advice.
Announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07187570?term=medical+device